We established an animal model of breakthrough cancer pain for the first time which shows high resemblance compared to the breakthrough cancer pain in human clinically.

The animal model of breakthrough cancer pain was induced by endothelin-1. The selective ETA receptor antagonist BQ-123 could reverse breakthrough pain.

We studied the characteristics of pain behaviors such as hind limb use score and voluntary wheel running with the model.

We also studied the electrophysiology of sciatic nerve fiber in corresponding to the pain behaviors with the model.

The model provides a platform for further study of the pathogenesis of breakthrough cancer pain and related targeted intervention.